CN103285123B - 黄皮果提取物在防治药源性肝炎药物中的应用 - Google Patents
黄皮果提取物在防治药源性肝炎药物中的应用 Download PDFInfo
- Publication number
- CN103285123B CN103285123B CN201310247660.5A CN201310247660A CN103285123B CN 103285123 B CN103285123 B CN 103285123B CN 201310247660 A CN201310247660 A CN 201310247660A CN 103285123 B CN103285123 B CN 103285123B
- Authority
- CN
- China
- Prior art keywords
- clausenae lansii
- fructus clausenae
- extract
- medicine
- lansii extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 244000089795 Clausena lansium Species 0.000 title claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title abstract description 12
- 235000008738 Clausena lansium Nutrition 0.000 title abstract description 10
- 206010072268 Drug-induced liver injury Diseases 0.000 title abstract description 7
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 title abstract description 6
- 201000008865 drug-induced hepatitis Diseases 0.000 title abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000006228 supernatant Substances 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- 238000001291 vacuum drying Methods 0.000 claims abstract description 4
- 208000006454 hepatitis Diseases 0.000 claims description 22
- 231100000283 hepatitis Toxicity 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 229930003944 flavone Natural products 0.000 claims description 6
- 235000011949 flavones Nutrition 0.000 claims description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 235000013824 polyphenols Nutrition 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 230000007159 enucleation Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000005493 rutin Nutrition 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 238000002798 spectrophotometry method Methods 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 5
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 238000010992 reflux Methods 0.000 abstract description 2
- 241001292317 Clausena Species 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 12
- 230000004761 fibrosis Effects 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000002440 hepatic effect Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 206010019692 hepatic necrosis Diseases 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 229960003350 isoniazid Drugs 0.000 description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002365 anti-tubercular Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229950000628 silibinin Drugs 0.000 description 2
- 235000014899 silybin Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- WGYGSZOQGYRGIP-MWDXBVQZSA-N (3r,4s,5s)-3-hydroxy-5-[(r)-hydroxy(phenyl)methyl]-1-methyl-4-phenylpyrrolidin-2-one Chemical class C1([C@@H](O)[C@H]2N(C([C@H](O)[C@H]2C=2C=CC=CC=2)=O)C)=CC=CC=C1 WGYGSZOQGYRGIP-MWDXBVQZSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940049413 rifampicin and isoniazid Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310247660.5A CN103285123B (zh) | 2013-06-20 | 2013-06-20 | 黄皮果提取物在防治药源性肝炎药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310247660.5A CN103285123B (zh) | 2013-06-20 | 2013-06-20 | 黄皮果提取物在防治药源性肝炎药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103285123A CN103285123A (zh) | 2013-09-11 |
CN103285123B true CN103285123B (zh) | 2015-04-22 |
Family
ID=49087012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310247660.5A Active CN103285123B (zh) | 2013-06-20 | 2013-06-20 | 黄皮果提取物在防治药源性肝炎药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103285123B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103637105A (zh) * | 2013-11-26 | 2014-03-19 | 郑州韩都药业集团有限公司 | 一种樱桃胶囊 |
CN104383052B (zh) * | 2014-12-01 | 2016-11-02 | 广东医学院 | 黄皮果提取物及其在制备用于防治阿尔茨海默病药物中的应用 |
CN105943450A (zh) * | 2016-06-18 | 2016-09-21 | 广州聚注专利研发有限公司 | 一种黄皮提取物及其制备方法和在化妆品中的应用 |
CN106174582A (zh) * | 2016-09-23 | 2016-12-07 | 广州正势生物科技有限公司 | 一种黄皮提取物的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3700706A1 (de) * | 1986-01-20 | 1987-07-23 | Bayer Ag | Neues bicyclisches lactam, pharmakologisch wirksame zubereitungen desselben, verfahren zu dessen herstellung und dessen verwendung in der medizin |
US4731456A (en) * | 1985-10-18 | 1988-03-15 | Bayer Aktiengesellschaft | Process for the preparation of clausenamide |
CN101045697A (zh) * | 2007-05-08 | 2007-10-03 | 暨南大学 | 黄皮核提取物及其制备方法 |
JP4585073B2 (ja) * | 2000-02-15 | 2010-11-24 | 丸善製薬株式会社 | 抗男性ホルモン剤、養毛化粧料、前立腺肥大抑制剤、外用剤及び飲食品 |
CN102030758A (zh) * | 2010-11-23 | 2011-04-27 | 苏州派腾生物医药科技有限公司 | 一种繸状芸香素的制备方法 |
-
2013
- 2013-06-20 CN CN201310247660.5A patent/CN103285123B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4731456A (en) * | 1985-10-18 | 1988-03-15 | Bayer Aktiengesellschaft | Process for the preparation of clausenamide |
DE3700706A1 (de) * | 1986-01-20 | 1987-07-23 | Bayer Ag | Neues bicyclisches lactam, pharmakologisch wirksame zubereitungen desselben, verfahren zu dessen herstellung und dessen verwendung in der medizin |
JP4585073B2 (ja) * | 2000-02-15 | 2010-11-24 | 丸善製薬株式会社 | 抗男性ホルモン剤、養毛化粧料、前立腺肥大抑制剤、外用剤及び飲食品 |
CN101045697A (zh) * | 2007-05-08 | 2007-10-03 | 暨南大学 | 黄皮核提取物及其制备方法 |
CN102030758A (zh) * | 2010-11-23 | 2011-04-27 | 苏州派腾生物医药科技有限公司 | 一种繸状芸香素的制备方法 |
Non-Patent Citations (5)
Title |
---|
Antioxidant and Anticancer Activities of Wampee (Clausena lansium (Lour.) Skeels) Peel;K. Nagendra Prasad, et al;《Journal of Biomedicine and Biotechnology》;20091231;第2009卷(第612805期);第1-6页,尤其是第2页左栏2.3项下 * |
EFFECT OF CLAUSENA DENTATA (WILLD.) M. ROEM. AGAINST PARACETAMOL INDUCED HEPATOTOXICITY IN RATS;SV RAJESH,et al.;《Pak. J. Pharm. Sci.》;20090131;第22卷(第1期);第90-93页 * |
大孔吸附树脂分离黄皮果中抗氧化成分的方法;钟秋平;《钦州师范高等专科学校学报》;20060630;第21卷(第3期);101-104页 尤其是第101页左栏第1段、右栏第1.3 样品的制备项下,第102页左栏1.5 树脂的预处理项下,第104页右栏 3结论项下 * |
微波辅助提取山黄皮果中的黄酮类物质;梁云贞等;《安徽农业科学》;20101231;第38卷(第14期);第7276-7271页 * |
黄皮果提取物对急性乙醇中毒致小鼠肝损伤的保护作用;官堂明等;《中国药理学与毒理学杂志》;20121231;第26卷(第6期);第829-834页 尤其是第830页左栏1.2项下,右栏2.1项下 * |
Also Published As
Publication number | Publication date |
---|---|
CN103285123A (zh) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100548323C (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN103285123B (zh) | 黄皮果提取物在防治药源性肝炎药物中的应用 | |
CN106798762A (zh) | 一种植物提取物及其制备方法和应用 | |
CN104721301B (zh) | 一种苹果多酚乙醇提取物及其制备方法和应用 | |
Chen et al. | Preparation and evaluation of PEGylated asiatic acid nanostructured lipid carriers on anti-fibrosis effects | |
CN108888670A (zh) | 一种治疗溃疡性结肠炎的结肠靶向胶囊剂及其制备工艺 | |
CN101972385B (zh) | 虎眼万年青总黄酮的制备方法及在抗肿瘤和抗炎止痛药物中的应用 | |
CN106038700A (zh) | 密蒙花及其提取物作为制备治疗肺源性心脏病的药物的应用 | |
CN105125601A (zh) | 一种赶黄草的提取物及其制备方法和用途 | |
CN103655929A (zh) | 一种具有护肝作用药物组合物及其制备方法 | |
CN106421208A (zh) | 一种具有抗化学性肝损伤功能的药物组合物及其制备方法 | |
CN104257811A (zh) | 一种保肝的食品、保健品或药物组合物 | |
CN106983746A (zh) | 一种药物组合物及其用途 | |
CN100391489C (zh) | 含有冰片的药物组合物 | |
CN105168520A (zh) | 一种黑老虎提取物的制备方法及在治疗非酒精性脂肪肝中的应用 | |
CN104856986A (zh) | 5-羟甲基糠醛在制备抗肝纤维化药物中的新用途 | |
CN102293847B (zh) | 一种用于治疗便秘、痤疮及高血脂的中药组合物及其制备方法 | |
Goswami et al. | Pharmacological Significance of Catharanthus roseus in Cancer Management: A Review | |
CN103830288B (zh) | 赛葵总黄酮提取物及其制备方法和用途 | |
CN105943681A (zh) | 具有改善胰岛素抵抗作用的荔枝核甾体皂苷提取物 | |
CN104510884A (zh) | 一种治疗心脑血管疾病的复方中药制剂 | |
CN109481502A (zh) | 一种香椿提取物的制备方法 | |
CN107898888A (zh) | 一种治疗脑卒中的中药复方制剂及其制备方法和应用 | |
CN107050012A (zh) | 一种具有美白祛斑作用的甘草黄酮微海绵及其制备方法和应用 | |
CN101912573B (zh) | 一种治疗癌症的靶向中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 524002 No. 2, Wenming East Road, Xiashan, Zhanjiang City, Guangdong Province Patentee after: Guangdong Medical University Address before: 524023 No. 2 civilized East Road, Xiashan District, Guangdong, Zhanjiang Patentee before: GUANGDONG MEDICAL College |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221010 Address after: Liusha Port, Qindou Town, Leizhou City, Zhanjiang City, Guangdong Province, 524147 Patentee after: Guangdong Zunding Pearl Co.,Ltd. Address before: 524002 No. 2, Wenming East Road, Xiashan, Zhanjiang City, Guangdong Province Patentee before: Guangdong Medical University |
|
TR01 | Transfer of patent right |